Benzodiazepine Reversal: A Comprehensive Guide to Flumazenil Use in Emergency and Postoperative Settings

Benzodiazepine overdose and the lingering sedation following benzodiazepine-based anesthesia pose significant challenges in clinical settings. Flumazenil, a potent benzodiazepine antagonist, emerges as a critical intervention in these scenarios. This article serves as an in-depth guide for healthcare professionals, providing essential knowledge on flumazenil for effective benzodiazepine Reversal For Benzo. We will explore its indications, mechanism of action, appropriate dosing, potential adverse effects, contraindications, necessary monitoring, and management of toxicity, empowering clinicians to optimize patient outcomes in benzodiazepine reversal situations.

FDA-Approved Indications for Flumazenil

Flumazenil is primarily recognized and approved by the FDA for its efficacy as a benzodiazepine antagonist. Its applications are crucial in emergency medicine and postoperative care.

Benzodiazepine Overdose Reversal

Flumazenil stands as a definitive treatment for benzodiazepine overdose in both adult and pediatric patients. Classified as a Category B, Class IIa intervention for adults and Category C, Class IIb for pediatrics, it underscores its established role in reversing the life-threatening central nervous system depression caused by excessive benzodiazepine intake. In cases of confirmed or suspected benzodiazepine overdose, timely administration of flumazenil can be life-saving, rapidly restoring consciousness and respiratory function.

Postoperative Sedation Reversal from Benzodiazepine Anesthetics

In the realm of anesthesia, benzodiazepines are frequently employed for their sedative and anxiolytic properties. Flumazenil plays a vital role in reversing the residual sedative effects of these anesthetics post-surgery, in both adult (Category B, Class IIa) and pediatric (Category B, Class IIa) populations. By counteracting the benzodiazepines, flumazenil facilitates a quicker and smoother emergence from anesthesia, reducing the duration of postoperative monitoring and enabling earlier patient discharge, particularly after minor surgical procedures.

Reversal of Sedation in Conscious Sedation and General Anesthesia

Flumazenil is explicitly indicated for the complete or partial reversal for benzo sedative effects induced during conscious sedation and general anesthesia. Its action is effective across all age groups, from pediatrics to adults. This capability is instrumental in procedures requiring patient cooperation or when rapid awakening is desired at the conclusion of a procedure.

Expediting Recovery and Shortening Post-Anesthesia Care

Beyond simply reversing sedation, flumazenil accelerates overall recovery from benzodiazepine-induced sedation following minor surgeries. This expedited recovery directly translates to a reduced post-anesthesia monitoring period. By diminishing the time patients need to spend in recovery, flumazenil enhances hospital efficiency and patient throughput, contributing to a more positive patient experience.

Management of Benzodiazepine Overdose-Induced Coma

Flumazenil is particularly effective in managing and treating coma resulting from benzodiazepine overdose in adults. Its targeted action on benzodiazepine receptors allows it to effectively awaken patients from a comatose state caused by benzodiazepine intoxication. However, it’s important to note that flumazenil’s efficacy is most pronounced in cases of isolated benzodiazepine overdose, and may be less effective when multiple substances are involved.

Off-Label Applications of Flumazenil

While primarily approved for benzodiazepine reversal, flumazenil has found several off-label uses, highlighting its potential in broader clinical scenarios.

Alcohol Withdrawal Syndrome

Although not a standard treatment, flumazenil has been explored in managing alcohol withdrawal syndrome. Its use in this context is based on the understanding that alcohol and benzodiazepines share some mechanisms of action on GABA receptors. However, it’s crucial to note that this is an off-label application and should be approached with caution, especially given the risks associated with withdrawal seizures.

Baclofen Reversal

Baclofen, a GABA-B receptor agonist, can cause sedation and respiratory depression in overdose. Flumazenil, acting on GABA-A receptors, has been investigated for its potential to reverse baclofen-induced central nervous system depression. While evidence is limited, some case reports suggest potential benefit in reversing baclofen toxicity.

Idiopathic Recurring Stupor

In rare cases of idiopathic recurring stupor, where the cause of recurrent episodes of unresponsiveness is unclear, flumazenil has been used diagnostically and therapeutically. If stupor is benzodiazepine-related or involves similar receptor mechanisms, flumazenil may offer temporary relief and diagnostic insight.

Cannabis Toxicity

Cannabis toxicity, particularly with synthetic cannabinoids, can present with symptoms including sedation and altered mental status. Flumazenil has been explored as a potential reversal agent in severe cases, although its effectiveness is not well-established and its use remains off-label and experimental.

Hepatic Encephalopathy

Hepatic encephalopathy, a complication of liver disease, can involve altered mental status and coma. Flumazenil has been studied for its ability to temporarily improve overt hepatic encephalopathy symptoms. However, it is important to note that studies indicate only transient symptomatic improvement without any demonstrated long-term survival benefits. Thus, flumazenil is not a primary treatment for hepatic encephalopathy.

Benzodiazepine Detoxification

Flumazenil has been investigated as an adjunct in benzodiazepine detoxification protocols, particularly for accelerating the process in individuals with dependence. Continuous infusion of flumazenil has been explored to facilitate a smoother and faster detoxification process, though this approach is not widely standard and requires careful monitoring to avoid withdrawal symptoms.

Image alt text: Diagram illustrating Flumazenil’s competitive antagonism at the benzodiazepine receptor site on the GABA-A receptor complex, effectively reversing the effects of benzodiazepines.

Mechanism of Action

Flumazenil operates as a competitive benzodiazepine antagonist. It exerts its effects by selectively binding to the benzodiazepine receptor site on the gamma-aminobutyric acid (GABA) A receptor complex. This competitive binding effectively blocks benzodiazepines and non-benzodiazepine substances from interacting with this receptor site. Crucially, flumazenil can displace benzodiazepines already bound to these receptors, effectively reversing their pharmacological actions.

Upon intravenous administration, flumazenil rapidly antagonizes the central nervous system depressant effects of benzodiazepines, including sedation, memory impairment, and psychomotor deficits. Its targeted mechanism makes it highly effective in reversing benzodiazepine-induced effects without directly affecting other neurotransmitter systems.

Pharmacokinetics

Understanding flumazenil’s pharmacokinetic profile is essential for appropriate dosing and anticipating its duration of action.

Absorption

Following intravenous administration, flumazenil acts swiftly. The onset of action is typically within 1 to 2 minutes, with approximately 80% of its effect achieved within the first 3 minutes. Peak effect is usually observed between 6 to 10 minutes post-administration.

Distribution

Flumazenil exhibits extensive distribution throughout the extracellular space in the body. Its initial apparent volume of distribution is approximately 0.5 L/kg, increasing to a steady-state volume of 0.9 to 1.1 L/kg. Plasma protein binding is around 50%, with albumin accounting for about two-thirds of this binding.

Metabolism

Flumazenil undergoes near-complete metabolism in the liver. It is primarily metabolized by hepatic enzymes, with metabolites being largely inactive. Only minor fractions of the drug are excreted unchanged.

Elimination

Elimination of flumazenil is rapid and primarily through renal excretion. Radiolabeled studies show that elimination is essentially complete within 72 hours, with 90% to 95% of radioactivity excreted in urine and 5% to 10% in feces. Hepatic metabolism is the primary route of clearance, with total clearance rates in healthy volunteers ranging from 0.8 to 1.0 L/hr/kg. The elimination half-life is approximately 54 minutes, with a variability of 21% (ranging from 41 to 79 minutes). This relatively short half-life is clinically significant as it can lead to re-sedation within 1 to 2 hours after administration, necessitating careful monitoring and potential repeat dosing.

Administration

Flumazenil is exclusively formulated for intravenous (IV) infusion.

Available Dosage Forms and Strengths

Flumazenil is available as an injectable solution with a concentration of 0.1 mg/mL. The solution maintains stability for 24 hours when stored in a syringe or when mixed with common IV fluids such as D5W (5% dextrose in water), Lactated Ringer’s (LR), or normal saline (NS). Administration is typically performed via free-flowing IV infusion into a large vein or through a series of small, fractionated injections.

Adult Dosage

Dosage guidelines vary based on the clinical scenario, whether it’s for benzodiazepine overdose management or reversal of sedation.

Benzodiazepine Overdose Management

For benzodiazepine overdose, the recommended adult dosing is as follows:

• Initial Dose: 0.2 mg IV administered over 30 seconds.
• Repeat Doses: If the desired level of consciousness is not achieved within 30 seconds, administer an additional 0.3 mg IV over 30 seconds.
• Subsequent Doses: Repeat doses of 0.5 mg IV over 30 seconds at 1-minute intervals, up to a maximum cumulative dose of 3 mg.
• Partial Response: Patients showing only a partial response to a 3 mg cumulative dose may require further slow titration up to a total dosage of 5 mg.
• Lack of Response: If no significant response is observed after a 5 mg dose, benzodiazepine is unlikely to be the primary cause of sedation, and further flumazenil administration is generally ineffective.
• Re-sedation Management: In cases of recurrent sedation, repeat doses may be given at 20-minute intervals, not exceeding 1 mg (administered at 0.5 mg/minute) per dose, or a total of 3 mg per hour.

Benzodiazepine Reversal in Conscious Sedation or General Anesthesia

For reversing benzodiazepine sedation in conscious sedation or general anesthesia, the adult dosage is:

• Initial Dose: 0.2 mg IV over 15 seconds.
• Repeat Doses: If the desired level of consciousness is not attained after 45 seconds, repeat doses of 0.2 mg IV may be administered at 1-minute intervals, if required.
• Maximum Cumulative Dose: A maximum total cumulative dose of 1 mg is generally recommended in this setting.
• Re-sedation Management: For re-sedation, repeat doses can be given at 20-minute intervals, not exceeding 0.2 mg/minute per dose or a total of 3 mg per hour.

Hepatic Encephalopathy

It is critical to note that for hepatic encephalopathy, flumazenil provides only transient improvement in overt symptoms without impacting long-term outcomes. It is not a recommended standard treatment for this condition.

Specific Patient Populations

Dosage adjustments and considerations are necessary for certain patient populations.

Hepatic Impairment

Patients with hepatic impairment require adjusted dosing. While the initial dose for benzodiazepine reversal for benzo remains the same, subsequent doses should be reduced in dosage or frequency due to decreased flumazenil metabolism and prolonged half-life in liver dysfunction.

Renal Impairment

For patients with renal impairment, including creatinine clearance <10 mL/min, no specific dosage adjustments are outlined in FDA-approved labeling. However, clinical judgment should always be exercised.

Pregnancy Considerations

Flumazenil has been used in pregnant individuals experiencing benzodiazepine toxicity. In cases where supportive measures are insufficient, flumazenil has demonstrated the potential to reverse fetal cardiac rhythm abnormalities induced by maternal benzodiazepine overdose, such as diazepam.

Breastfeeding Considerations

Caution is advised when administering flumazenil to breastfeeding women, as its presence in human milk is not fully established. Limited data exists; however, given its short half-life, breastfeeding can potentially continue if the mother requires flumazenil. To minimize infant exposure, abstaining from breastfeeding for 4 to 5 hours post-administration may be considered.

Pediatric Patients

In pediatric patients, flumazenil is indicated for benzodiazepine reversal for benzo in conscious sedation or general anesthesia.

• Initial Dose: 0.01 mg/kg administered over 15 seconds (up to a maximum dose of 0.2 mg).
• Repeat Doses: If the desired consciousness level is not achieved after 45 seconds, repeat 0.01 mg/kg (up to 0.2 mg) at 1-minute intervals as needed, up to 4 additional doses.
• Maximum Cumulative Dose: The maximum total cumulative dose is 1 mg or 0.05 mg/kg, whichever is lower.
• Mean Total Dose in Trials: Clinical trials showed a mean total dose of 0.65 mg (range 0.08 to 1 mg) was administered.

Older Patients

Studies indicate that while benzodiazepine doses for sedation in older adults should be reduced, the standard flumazenil dosage remains effective for reversal for benzo in this population.

Adverse Effects

While generally safe when used appropriately, flumazenil can be associated with adverse effects, ranging from common to serious.

Serious Adverse Events

Serious adverse events associated with flumazenil include:

• Sedation: Paradoxical re-sedation can occur due to flumazenil’s short half-life compared to longer-acting benzodiazepines.
• Neurologic Effects: These can range from agitation and confusion to seizures, particularly in patients with benzodiazepine dependence or mixed overdoses.
• Seizures: Flumazenil can precipitate seizures, especially in individuals with pre-existing seizure disorders or benzodiazepine withdrawal.
• Arrhythmias: Cardiac arrhythmias have been reported, though less commonly.

Common Adverse Events

Common adverse events are more frequently observed and generally less severe:

Cardiovascular:

• Bradycardia
• Tachycardia
• Hypertension
• Chest pain

Neurologic:

• Confusion
• Dizziness
• Headache
• Impaired cognition
• Opisthotonus (muscle spasms)
• Shivering
• Somnolence

Gastrointestinal:

• Nausea
• Vomiting

Immunologic:

• Injection site reaction

Ophthalmic:

• Visual field defects and diplopia (double vision)
• Blurred vision

Otic:

• Transient hearing impairment

Dermatologic:

• Diaphoresis (excessive sweating)
• Injection site pain

Psychiatric:

• Anxiety
• Psychotic disorder
• Agitation
• Panic attack

Drug-Drug Interactions

Potential drug interactions should be carefully considered when administering flumazenil.

Tricyclic Antidepressants (TCAs)

Extreme caution is warranted when using flumazenil in mixed drug overdoses, especially those involving tricyclic antidepressants (TCAs) like amitriptyline, nortriptyline, clomipramine, and imipramine. The risk of seizures is significantly increased in this context. In severe TCA toxicity characterized by dysrhythmias, anticholinergic signs, and cardiovascular collapse, flumazenil is contraindicated. Supportive care should be prioritized until TCA toxicity symptoms subside.

Vecuronium

A practical consideration is the potential for medication errors due to visual similarities between vials of flumazenil and vecuronium (a neuromuscular blocker) after removing their colored caps. Both may be stored in procedural areas, increasing the risk of mix-up. Careful labeling and verification processes are crucial to prevent accidental administration.

Contraindications

Flumazenil use is contraindicated in specific clinical scenarios.

Absolute Contraindications

• Hypersensitivity: Known hypersensitivity to flumazenil or benzodiazepines.
• Benzodiazepine Use for Life-Threatening Conditions: When benzodiazepines are used to control life-threatening conditions like increased intracranial pressure or status epilepticus, their reversal is contraindicated as it could exacerbate the underlying condition.

Warnings and Precautions

Several warnings and precautions should guide flumazenil administration:

• Panic Disorder: Flumazenil can provoke panic attacks in patients with a history of panic disorder due to the abrupt reversal of benzodiazepine effects.
• Chronic Benzodiazepine Dependency: Convulsions may be precipitated in patients with chronic benzodiazepine dependence due to acute withdrawal.
• Head Injury: Flumazenil may increase the risk of convulsions or alter cerebral blood flow in patients with head injuries.
• Epilepsy: Increased seizure risk exists in epileptic patients who have been treated with benzodiazepines for prolonged periods.
• Drug Dependency or Alcoholism: Caution is advised in patients with drug dependency or alcoholism due to a higher incidence of benzodiazepine tolerance and dependence.
• Severe Lung Disease: Avoid use as primary treatment in patients with severe lung disease where respiratory depression is secondary to benzodiazepines, as reversing benzodiazepine effects may not resolve the primary respiratory issue.
• Tricyclic Antidepressant Overdose: Signs of TCA overdose or mixed overdoses are a strong caution against flumazenil use due to seizure risk.

Image alt text: Illustration depicting the intravenous administration of Flumazenil, highlighting the recommended route for effective benzodiazepine reversal in clinical settings.

Monitoring

Post-flumazenil administration monitoring is crucial for patient safety.

Essential Monitoring Parameters

Patients require close monitoring for at least 2 hours following flumazenil administration for:

• Respiratory Depression: To detect any recurrence due to benzodiazepine re-sedation or other factors.
• Benzodiazepine Withdrawal: Especially in chronic users, to manage potential withdrawal symptoms.
• Residual Benzodiazepine Effects: To assess for any lingering sedative effects.

Seizure Precautions

Be vigilant for seizures, which can occur secondary to flumazenil administration, particularly in susceptible individuals. Seizures induced by flumazenil may necessitate treatment with benzodiazepines, potentially requiring larger doses than initially used.

Re-Sedation Management

Monitor for the possible return of sedation, especially in patients tolerant to benzodiazepines or in cases of long-acting benzodiazepine overdose. Re-sedation can be managed by administering repeat doses of flumazenil until the desired therapeutic effect is achieved.

Toxicity

Flumazenil overdose is exceedingly rare. However, understanding its toxicity profile is important.

Clinical Features of Overdose

In the rare event of flumazenil toxicity, clinical features may include:

• Anxiety
• Agitation
• Increased muscle tone (hypertonia)
• Heightened sensitivity to stimuli (hyperesthesia)
• Seizures

Management of Toxicity

Currently, there is no specific antidote for flumazenil toxicity. Management is primarily supportive and symptomatic, addressing clinical manifestations as they arise.

Consultation Criteria

In cases of suspected severe adverse effects following flumazenil administration, such as seizures, dysrhythmias, or hypotension, prompt consultation with a medical toxicologist or a regional poison control center is recommended.

Enhancing Healthcare Team Outcomes

In the context of escalating drug overdoses, proficiency in using flumazenil is vital for nurses, pharmacists, and physicians. While flumazenil offers rapid benzodiazepine reversal for benzo, its application is not without complexities. It is crucial to recognize that the effects of flumazenil can be inconsistent and unpredictable, and it carries risks, including precipitating seizures and withdrawal, particularly in patients with chronic benzodiazepine use or certain medical conditions.

Healthcare providers should be acutely aware of contraindications, especially in patients with a history of seizures, head injury, or tricyclic antidepressant ingestion. The ideal scenario for flumazenil use is in cases of benzodiazepine overdose in individuals without chronic benzodiazepine exposure or these contraindications.

Nurses and pharmacists play a crucial role in educating patients about benzodiazepines, emphasizing their addictive potential and risks of physical dependence. In isolated benzodiazepine overdoses, supportive management alone may often suffice, as significant mortality is rare in these cases. Flumazenil use in routine benzodiazepine overdose management is becoming more selective due to the potential for adverse effects outweighing benefits in certain populations.

Effective management of benzodiazepine overdose and flumazenil administration requires a collaborative, interprofessional team approach. Emergency department clinicians, hospital pharmacists ensuring correct dosing, critical care specialists for severe cases, and medical toxicologists for complex multiple-drug ingestions all contribute to optimizing patient outcomes and minimizing risks associated with flumazenil therapy. This coordinated strategy ensures maximum efficacy and patient safety in benzodiazepine reversal scenarios.

References

1. Baandrup L, Ebdrup BH, Rasmussen JØ, Lindschou J, Gluud C, Glenthøj BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018 Mar 15;3(3):CD011481. [PMC free article: PMC6513394] [PubMed: 29543325]
2. Zhu S, Noviello CM, Teng J, Walsh RM, Kim JJ, Hibbs RE. Structure of a human synaptic GABAA receptor. Nature. 2018 Jul;559(7712):67-72. [PMC free article: PMC6220708] [PubMed: 29950725]
3. Practice Guidelines for Moderate Procedural Sedation and Analgesia 2018: A Report by the American Society of Anesthesiologists Task Force on Moderate Procedural Sedation and Analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology, American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology. Anesthesiology. 2018 Mar;128(3):437-479. [PubMed: 29334501]
4. Seelhammer TG, DeGraff EM, Behrens TJ, Robinson JC, Selleck KL, Schroeder DR, Sprung J, Weingarten TN. [The use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes]. Braz J Anesthesiol. 2018 Jul-Aug;68(4):329-335. [PMC free article: PMC9391726] [PubMed: 29631877]
5. Wu Q, Xu F, Wang J, Jiang M. Comparison of Remimazolam-Flumazenil versus Propofol for Recovery from General Anesthesia: A Systematic Review and Meta-Analysis. J Clin Med. 2023 Nov 26;12(23) [PMC free article: PMC10707179] [PubMed: 38068368]
6. Nelson LS. Alcohol withdrawal and flumazenil: not for the faint of heart. J Med Toxicol. 2014 Jun;10(2):123-5. [PMC free article: PMC4057543] [PubMed: 24595919]
7. Franchitto N, Pelissier F, Lauque D, Simon N, Lançon C. Self-intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series. Alcohol Alcohol. 2014 Jan-Feb;49(1):79-83. [PubMed: 24226812]
8. Asthana V, Agrawal S, Goel D, Sharma JP. Idiopathic recurrent stupor mimicking status epilepticus. Singapore Med J. 2008 Oct;49(10):e276-7. [PubMed: 18946597]
9. Crippa JA, Derenusson GN, Chagas MH, Atakan Z, Martín-Santos R, Zuardi AW, Hallak JE. Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm Reduct J. 2012 Jan 25;9:7. [PMC free article: PMC3294246] [PubMed: 22273390]
10. Reinert JP, Burnham K. Non-Lactulose Medication Therapies for the Management of Hepatic Encephalopathy: A Literature Review. J Pharm Pract. 2021 Dec;34(6):922-933. [PubMed: 32878558]
11. Benini A, Gottardo R, Chiamulera C, Bertoldi A, Zamboni L, Lugoboni F. Continuous Infusion of Flumazenil in the Management of Benzodiazepines Detoxification. Front Psychiatry. 2021;12:646038. [PMC free article: PMC8012511] [PubMed: 33815177]
12. An H, Godwin J. Flumazenil in benzodiazepine overdose. CMAJ. 2016 Dec 06;188(17-18):E537. [PMC free article: PMC5135539] [PubMed: 27920113]
13. Amrein R, Hetzel W, Hartmann D, Lorscheid T. Clinical pharmacology of flumazenil. Eur J Anaesthesiol Suppl. 1988;2:65-80. [PubMed: 2842143]
14. van Rij CM, Huitema AD, Swart EL, Greuter HN, Lammertsma AA, van Loenen AC, Franssen EJ. Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. Br J Clin Pharmacol. 2005 Nov;60(5):477-85. [PMC free article: PMC1884950] [PubMed: 16236037]
15. Kiyama S. Re-sedation after a large dose of flumazenil. J Anesth. 2023 Feb;37(1):161. [PubMed: 36242628]
16. Parthvi R, Mehra S. Flumazenil for Mixed Drug Overdose. Am J Ther. 2018 Nov/Dec;25(6):e676-e677. [PubMed: 28708699]
17. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 Aug;60(2):715-35. [PubMed: 25042402]
18. Janssen U, Walker S, Maier K, von Gaisberg U, Klotz U. Flumazenil disposition and elimination in cirrhosis. Clin Pharmacol Ther. 1989 Sep;46(3):317-23. [PubMed: 2505960]
19. Zelner I, Matlow J, Hutson JR, Wax P, Koren G, Brent J, Finkelstein Y., Toxicology Investigators Consortium (ToxIC). Acute Poisoning During Pregnancy: Observations from the Toxicology Investigators Consortium. J Med Toxicol. 2015 Sep;11(3):301-8. [PMC free article: PMC4547956] [PubMed: 25783189]
20. Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Aug 15, 2023. Flumazenil. [PubMed: 37603673]
21. Penninga EI, Graudal N, Ladekarl MB, Jürgens G. Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication–A Systematic Review with Meta-Analyses of Randomised Trials. Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):37-44. [PubMed: 26096314]
22. Wong M. Reversal Agents in Sedation and Anesthesia Practice for Dentistry. Anesth Prog. 2022 Apr 01;69(1):49-58. [PMC free article: PMC8985463] [PubMed: 35377935]
23. Veiraiah A, Dyas J, Cooper G, Routledge PA, Thompson JP. Flumazenil use in benzodiazepine overdose in the UK: a retrospective survey of NPIS data. Emerg Med J. 2012 Jul;29(7):565-9. [PubMed: 21785147]
24. Grissinger M. Paralyzed by Mistakes – Reassess the Safety of Neuromuscular Blockers in Your Facility. P T. 2019 Mar;44(3):91-107. [PMC free article: PMC6385733] [PubMed: 30828226]
25. Woolf AD, Erdman AR, Nelson LS, Caravati EM, Cobaugh DJ, Booze LL, Wax PM, Manoguerra AS, Scharman EJ, Olson KR, Chyka PA, Christianson G, Troutman WG. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(3):203-33. [PubMed: 17453872]
26. Seger DL. Flumazenil–treatment or toxin. J Toxicol Clin Toxicol. 2004;42(2):209-16. [PubMed: 15214628]
27. Haverkos GP, DiSalvo RP, Imhoff TE. Fatal seizures after flumazenil administration in a patient with mixed overdose. Ann Pharmacother. 1994 Dec;28(12):1347-9. [PubMed: 7696723]
28. Sivilotti ML. Flumazenil, naloxone and the ‘coma cocktail’. Br J Clin Pharmacol. 2016 Mar;81(3):428-36. [PMC free article: PMC4767210] [PubMed: 26469689]
29. Lavonas EJ, Akpunonu PD, Arens AM, Babu KM, Cao D, Hoffman RS, Hoyte CO, Mazer-Amirshahi ME, Stolbach A, St-Onge M, Thompson TM, Wang GS, Hoover AV, Drennan IR., American Heart Association. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2023 Oct 17;148(16):e149-e184. [PubMed: 37721023]
30. Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther. 1992 Mar-Apr;14(2):292-305. [PubMed: 1611650]
31. Rousseau-Blass F, Cribb AE, Beaudry F, Pang DS. A Pharmacokinetic-Pharmacodynamic Study of Intravenous Midazolam and Flumazenil in Adult New Zealand White-Californian Rabbits (Oryctolagus cuniculus). J Am Assoc Lab Anim Sci. 2021 May 01;60(3):319-328. [PMC free article: PMC8145127] [PubMed: 33673881]
32. Maxa JL, Ogu CC, Adeeko MA, Swaner TG. Continuous-infusion flumazenil in the management of chlordiazepoxide toxicity. Pharmacotherapy. 2003 Nov;23(11):1513-6. [PubMed: 14620397]
33. Wallace IR, Campbell EC, Trimble M. Use of a flumazenil infusion to treat chlordiazepoxide toxicity. Acute Med. 2017;16(1):30-34. [PubMed: 28424803]
34. Vukcević NP, Ercegović GV, Segrt Z, Djordjević S, Stosić JJ. Benzodiazepine poisoning in elderly. Vojnosanit Pregl. 2016 Mar;73(3):234-8. [PubMed: 27295906]
35. Kreshak AA, Cantrell FL, Clark RF, Tomaszewski CA. A poison center’s ten-year experience with flumazenil administration to acutely poisoned adults. J Emerg Med. 2012 Oct;43(4):677-82. [PubMed: 22766408]
36. Tamburin S, Faccini M, Casari R, Federico A, Morbioli L, Franchini E, Bongiovanni LG, Lugoboni F. Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence. J Psychopharmacol. 2017 Oct;31(10):1369-1373. [PubMed: 28613124]
37. Tae CH, Kang KJ, Min BH, Ahn JH, Kim S, Lee JH, Rhee PL, Kim JJ. Paradoxical reaction to midazolam in patients undergoing endoscopy under sedation: Incidence, risk factors and the effect of flumazenil. Dig Liver Dis. 2014 Aug;46(8):710-5. [PubMed: 24893689]
38. Isbister GK, O’Regan L, Sibbritt D, Whyte IM. Alprazolam is relatively more toxic than other benzodiazepines in overdose. Br J Clin Pharmacol. 2004 Jul;58(1):88-95. [PMC free article: PMC1884537] [PubMed: 15206998]